Request an invite

Which animal species did regulators accept for approved gene therapies?

From the FDA and EMA reviews of all 26 approved gene therapies. Each answer links to the regulator's own sentence.

Check my plan against these
Short answer
12 of 26 approved gene therapies ran pivotal tox in: rodent only.
Monkey only1/26
Monkey + rodent11/26
Rodent only12/26
Other species2/26

Precedent by precedent

26 approved gene therapies, with the reviewers' own words.

Adstiladrin

nadofaragene firadenovec · IFN-alpha2b (adenovirus, intravesical)
Species
Cynomolgus monkey for rAd-IFN/Syn3 GLP tox; rat and monkey for excipient Syn3
“Rat and cynomolgus monkey have been used as the toxicology species for Syn3NODA and cynomolgus monkeys were used for the toxicological assessment of rAd-IFN/Syn3NODA.”
✓ VerifiedEMA assessment report, p. 28Source ↗
Why that species
Monkey shows systemic vector exposure after intravesical dosing (unlike rodents), a worst-case model; permissiveness not otherwise discussed
“As a toxicological species, monkeys may be a worst-case model, since systemic toxicity of rAd-IFN will be of very limited relevance to the clinical situation.”
✓ VerifiedEMA assessment report, p. 40Source ↗

Beqvez

fidanacogene elaparvovec · Factor IX
Species
Cynomolgus monkey and mouse (tox); hemophilia B dog and mouse (pharmacology); rabbit (shedding)
“A toxicology study was also conducted evaluating IV administration of AAVRh74var Padua in nonhuman primates (NHP) at dose levels ranging from 1 x 1012 vg/kg to 5 x 1012 vg/kg.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Why that species
Not stated in public reviews

Casgevy

exagamglogene autotemcel · BCL11A enhancer (CRISPR-Cas9, ex vivo HSC)
Species
Mouse only (irradiated NSG immunodeficient xenotransplant mice)
“The toxicity of exa-cel has been evaluated in an in vivo combined GLP toxicity and tumorigenicity study with a duration of 20 weeks in NSG mice.”
✓ VerifiedEMA assessment report, p. 43Source ↗
Why that species
No relevant disease model; NSG xenotransplant mice support engraftment of human edited cells (most relevant model)
“No in vivo proof-of-concept studies were conducted as no relevant animal disease model for TDT and SCD exists that could be used for evaluation of exa-cel.”
✓ VerifiedEMA assessment report, p. 39Source ↗

Elevidys

delandistrogene moxeparvovec · Micro-dystrophin
Species
Mouse only (wild-type C57BL/6J and mdx disease model); NHP only in non-GLP supporting studies
“The following toxicology studies were conducted to evaluate the safety of ELEVIDYS following administration in WT and mdx mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 31Source ↗
Why that species
Disease-model rodents (mdx mice, Dmdmdx rats) used to show micro-dystrophin expression and efficacy; no explicit species-relevance argument
“The pharmacology studies of ELEVIDYS were conducted in rodent models of DMD including mdx mice and Dmdmdx rats.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗

Fayuvi

rebisufligene etisparvovec · SGSH (AAV9)
Species
Wild-type C57BL/6 mice only (6-month and 3-month GLP studies)
“which investigated the effect of a single intravenous administration of 5.0x1012 to 5.0x1013 vg/kg scAAV9.U1a.SGSH in WT C57Bl/6 mice.”
✓ VerifiedFDA summary basis for approval, p. 11Source ↗
Why that species
Not stated in public reviews

Genglycos

pariglasgene brecaparvovec · G6PC (AAV8)
Species
Mouse (adult and juvenile C57BL/6N) and juvenile cynomolgus monkey; GLP single-dose studies
“Three separate 92-day, single-dose toxicology studies were conducted in healthy adult and juvenile mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Why that species
Not stated in public reviews

Glybera

alipogene tiparvovec · LPL (AAV1)
Species
Wild-type mouse only for GLP tox; PD in LPL-/- mice and LPL-deficient cats; biodistribution in cats, mice, rabbits
“All toxicity studies were performed in wild type mice in accordance with GLP.”
✓ VerifiedEMA assessment report, p. 27Source ↗
Why that species
Single species accepted per EU gene therapy guidelines; LPL-deficient mice and cats used as disease models
“The use of a single species for toxicity evaluation is in accordance with the guideline for gene therapy medicinal products EMEA/CHMP/GTWP/587488/2007 and the guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products (EMEA/CHMP/GTWP/12459/2006).”
✓ VerifiedEMA assessment report, p. 27Source ↗

Hemgenix

etranacogene dezaparvovec · Factor IX
Species
Mouse and cynomolgus monkey
“The toxicology data package of etranacogene dezaparvovec and AMT-060 included single IV dose toxicity studies up to duration of 6 months with 6 months observation period in C57Bl/6 mice and cynomolgus macaques, and a reproduction and developmental toxicity study in mice.”
✓ VerifiedEMA assessment report, p. 30Source ↗
Why that species
NHP most relevant as natural AAV host; mouse and monkey hepatocytes transduced and express hFIX
“From the pharmacokinetic point of view, non-human primates were the most relevant species”
✓ VerifiedEMA assessment report, p. 37Source ↗

Imlygic

talimogene laherparepvec · GM-CSF (oncolytic HSV-1)
Species
Mouse (BALB/c) for GLP tox; single-dose studies also in rats and dogs; no permissive/relevant species for human GM-CSF
“Exploratory and GLP-compliant repeat dose toxicity studies were conducted in Balb/c mice with up to 12 weekly doses.”
✓ VerifiedEMA assessment report, p. 35Source ↗
Why that species
Mouse used with mouse surrogate virus because human GM-CSF does not bind mouse receptor; human GM-CSF not bioactive in mice
“The expressed human GM-CSF is not bioactive in the mice, thus the findings are likely not related to exposure to this human protein.”
✓ VerifiedFDA pharmacology/toxicology review, p. 74Source ↗

Itvisma

onasemnogene abeparvovec (intrathecal) · SMN1 (AAV9, intrathecal)
Species
Cynomolgus monkey (pivotal IT tox); FVB mice for ICV safety and fertility/EFD; SMA piglet and SMN-delta7 mouse pharmacology
“In vivo toxicology/safety studies conducted in NHPs utilized a single IT administration of OAV101 at 1.2 x 1013 vg/animal, considered equivalent to the proposed starting clinical dose level for ITVISMA of 1.2x1014 vg/patient based on a 10-fold difference in CSF volume between NHP and human.”
✓ VerifiedFDA summary basis for approval, p. 15Source ↗
Why that species
NHP IT delivery transduces 55-79% of ChAT+ spinal motor neurons; CSF volume scaling NHP to human
“IT administration of scAAV9.CBA.SMN demonstrated a 55-79% transduction efficiency of choline acetyltransferase (ChAT) positive motor neurons in NHP spinal cords.”
✓ VerifiedFDA summary basis for approval, p. 15Source ↗

Kebilidi

eladocagene exuparvovec · AADC
Species
Rat (pivotal GLP); cynomolgus monkey for biodistribution/excipient studies
“The nonclinical safety program conducted to characterize the toxicity and biodistribution of eladocagene exuparvovec comprised of two studies, a 30-day study, and a 6 month study, both in rats.”
✓ VerifiedEMA assessment report, p. 38Source ↗
Why that species
Not stated in public reviews

Kresladi

marnetegragene autotemcel · ITGB2 (LVV, ex vivo HSC)
Species
Mouse only (CD18HYP/CD18KO disease models, recipient mice, NSG mice); no large-animal tox
“The applicant also used surrogate Lin- HSPCs transduced with the Chim-CD18-WPRE LV transplanted into recipient mice for their definitive in vivo toxicology and BD studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Why that species
CD18-deficient mice mimic LAD-I phenotype (impaired neutrophil migration); patient CD34+ cells unavailable
“CD18HYP and CD18KO mice have deficient CD18 expression and impaired neutrophil migration and inflammatory responses similar to LAD-I patients.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗

Lenmeldy

atidarsagene autotemcel · ARSA (LVV, ex vivo HSC)
Species
Mouse (As2-/- MLD model, murine ARSA-LV HSPCs) for pivotal GLP; immunodeficient mice for human-cell biodistribution
“The in vivo safety of single IV administration of ARSA LVV-transduced mHSPCs at 1x106 cells/mouse (40-50x106 cells/kg) in irradiated As2-/- mice was evaluated in a pivotal GLP study for up to 12 months post-transplant.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Why that species
As2-/- mouse used as MLD disease model; recapitulates some pathology but milder phenotype than patients
“The applicant has used the As2-/- mouse as a disease model for MLD in children.”
✓ VerifiedEMA assessment report, p. 42Source ↗

Luxturna

voretigene neparvovec · RPE65
Species
Dog (normal-sighted and RPE65-mutant Briard) and non-human primate
“Single dose and repeat dose toxicology studies were conducted in normal-sighted dogs, RPE65 mutant dogs, and normal-sighted non-human primates (NHPs).”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Why that species
RPE65-/- Briard dog is a natural large-animal disease model; eye size makes dog more relevant than mouse
“The applicant noted that relative transduction efficiency of AAV2 in RPE cells across species is not known but that, given the sizes of eye in dog and mouse, the studies in Briard dogs are more relevant to human effects than those in mice”
✓ VerifiedEMA assessment report, p. 21Source ↗

Lyfgenia

lovotibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
Species
Mouse only (beta-thalassemic and wild-type C57BL/6 transplant models; immunodeficient mice for human cells)
“The following toxicology studies were conducted to evaluate the safety of human HSCs or mBMCs transduced with BB305 LVV following administration in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 16Source ↗
Why that species
Beta-thalassemic (Hbbth1/th1) mouse disease model allowed pharmacology and toxicity assessment of transduced syngeneic marrow
“To evaluate the pharmacologic and toxicologic effects of mBMCs transduced with BB305 LVV or mBMCs transduced with HPV569 LVV following IV administration in β-thalassemic mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 17Source ↗

Otarmeni

lunsotogene parvec · OTOF (AAV, intracochlear)
Species
Mouse (Otof-Q828X hom disease model) and cynomolgus monkey
“Single-dose toxicology studies were conducted in Otof-Q828X hom mice and cynomolgus monkeys.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Why that species
Otof-Q828X mice recapitulate human deafness phenotype; monkey inner ear anatomy similar to human, clinical surgical approach
“This study provides the most clinically relevant procedural safety data, as it utilized the same RWM surgical approach intended for clinical use and was performed in monkeys with inner ear anatomy similar to humans.”
✓ VerifiedFDA pharmacology/toxicology review, p. 26Source ↗

Papzimeos

zopapogene imadenovec · HPV6/11 antigens (gorilla adenovirus)
Species
Mouse only (wild-type C57BL/6); no NHP studies
“The following toxicology study was conducted to evaluate the safety of PRGN-2012 following SC administration in WT mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Why that species
Mouse used for immunogenicity/safety; reviewer notes murine antigen processing likely differs from human T-cell recognition
“The dose level assessed in this non-GLP toxicology study provides a 5-fold safety factor for the clinical dose level with the caveat that the processing and binding sequences in wildtype mice is likely different than the peptides recognized by human T cells .”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗

Roctavian

valoctocogene roxaparvovec · Factor VIII
Species
Mouse (CD1, Rag2-/-, hemophilia A models) and cynomolgus/rhesus monkey; all males
“As the clinical schedule foresees one unique injection of BMN 270, all non-clinical studies supporting the safety of BMN 270 are single-dose toxicity studies conducted by the IV route, in male animals, in different animal species (Rag2-/- mice, Rag2-/- x FVIII-/- mice, CD1 mice, monkeys), which is acceptable.”
✓ VerifiedEMA assessment report, p. 30Source ↗
Why that species
Hemophilia A (Rag2-/- x FVIII-/-) mouse model for pharmacology; no explicit species-relevance argument; males because >99% of patients male
“All animals used in the nonclinical programme to evaluate BMN 270 were males because > 99% of HA patients are male.”
✓ VerifiedEMA assessment report, p. 19Source ↗

Skysona

elivaldogene autotemcel · ABCD1 (LVV, ex vivo HSC)
Species
Mouse only: myeloablated immunodeficient NSG/NSGS mice given human CD34+ HSCs
“pivotal combined in vivo pharmacology, single-dose toxicity, genotoxicity and biodistribution studies in immunodeficient (NSG and NSGS) mice”
✓ VerifiedEMA assessment report, p. 30Source ↗
Why that species
Human cells rejected by immunocompetent animals, so immune-incompetent mice used; species barrier limits translatability
“they will be rejected. Therefore immune”
✓ VerifiedEMA assessment report, p. 31Source ↗

Strimvelis

autologous CD34+ cells transduced with ADA (no INN) · ADA (gamma-retroviral, ex vivo HSC)
Species
NSG immunodeficient mouse only (xenograft of transduced human CD34+ cells)
“The use of NSG mouse strain (deficient in mature T/B/NK cells) for the non-clinical biodistribution/single-dose toxicology study after engraftment of CD34+ cells derived from healthy human UCB, transduced with GSK3336223 vector, was endorsed by the CAT/CHMP prior to MAA submission.”
✓ VerifiedEMA assessment report, p. 26Source ↗
Why that species
NSG supports human HSPC engraftment with longer survival and fewer spontaneous tumours than ADA-/- mice; no cross-reactivity issue (human cells)
“Subsequently, the results of two bio-distribution studies were submitted using the NSG mouse based on the reports presented that indicate this is a valid model for immunodeficient mice, which can be used as recipient of HSPC transplantation, with longer survival rates and reduced frequency of spontaneous tumours as compared to ADA-/- mice.”
✓ VerifiedEMA assessment report, p. 23Source ↗

Tudriqev

vusolimogene oderparepvec · GALV-GP + GM-CSF (oncolytic HSV-1)
Species
Tumor-bearing immunocompetent mice (TUDRIQEV, mRP1) and healthy rats (murine surrogate mRP1)
“Toxicology studies evaluating TUDRIQEV and mRP1 were conducted in tumor-bearing immunocompetent mice and healthy rats, respectively.”
✓ VerifiedFDA summary basis for approval, p. 13Source ↗
Why that species
Not stated in public reviews

Vyjuvek

beremagene geperpavec · COL7A1 (HSV-1, topical)
Species
Mouse only (BALB/c) for GLP tox; single species
“the use of a single species (mice) for the toxicity studies is considered acceptable and in line with the”
✓ VerifiedEMA assessment report, p. 34Source ↗
Why that species
No justification given beyond historical use of mice; mouse skin dissimilar to human; EB mouse and human RDEB xenograft used for pharmacology
“A justification for the choice of mice is not specified, other than the suggestion that this species is historically used in toxicity studies.”
✓ VerifiedEMA assessment report, p. 34Source ↗

Waskyra

etuvetidigene autotemcel · WAS (LVV, ex vivo HSC)
Species
Mouse only: WAS knockout (C57BL/6 and SV129) mice with murine surrogate cells; Rag2-/-IL2rg-/- mice for human-cell fate
“Two different WAS disease models were used to evaluate in vivo safety of transduced HSPCs: a WAS knockout (WKO) mouse on a C57BL/6 background”
✓ VerifiedEMA assessment report, p. 34Source ↗
Why that species
Autologous human cells cannot be used in animals; murine Lin- HSPCs functionally equivalent to human CD34+; Rag2-/-IL2rg-/- avoids immunogenicity
“The impossibility of using autologous human cells in animal models limits the scope of possible nonclinical studies.”
✓ VerifiedEMA assessment report, p. 40Source ↗

Zevaskyn

prademagene zamikeracel · COL7A1 (RV-modified keratinocyte sheets)
Species
Mouse only (immunodeficient mice with implanted human keratinocyte products); no relevant large-animal species
“In the toxicology and biodistribution (BD) study, nonclinical products representative of ZEVASKYN comprised of human acellular dermal matrix and RVV-transduced human keratinocytes (cells alone) were implanted into excisional wounds generated in mice for 4- or 8-weeks.”
✓ VerifiedFDA summary basis for approval, p. 12Source ↗
Why that species
Not stated in public reviews

Zolgensma

onasemnogene abeparvovec · SMN1
Species
Mouse only for pivotal GLP tox (neonatal FVB); NHP only in non-GLP studies (later 6-month juvenile NHP study in label)
“Single-dose toxicology studies were conducted to evaluate the safety of AVXS-101 following a single IV administration in healthy neonatal FVB/n mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 14Source ↗
Why that species
FVB/n strain chosen as background of SMNdelta7 disease model to compare with pharmacology data; EMA noted NHP closer to human
“The Applicant has chosen to use the FVB/n strain in the toxicology studies to be able to directly compare safety data from the SMNΔ7 studies.”
✓ VerifiedEMA assessment report, p. 35Source ↗

Zynteglo

betibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
Species
Mouse only (beta-thalassaemic Hbbth1/th1 and wild-type C57BL/6; immunodeficient NSG for human HSC); murine surrogate product
“BB305 LVV-transduced cells were evaluated in the β-thalassaemic (Hbbth1/th1) mouse model and in the NSG mice.”
✓ VerifiedEMA assessment report, p. 26Source ↗
Why that species
Thalassaemic mouse model gives disease-relevant POC; NSG mice cannot reject human CD34+ HSCs
“they are therefore unable to reject the human CD34+ HSCs.”
✓ VerifiedEMA assessment report, p. 30Source ↗